MDACC Study No:2012-0573 ( NCT No: NCT01568866)
Title:A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma
Principal Investigator:Michael Wang
Treatment Agent:Bortezomib; Carfilzomib; Dexamethasone
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the combination of
carfilzomib and dexamethasone to the combination of bortezomib (Velcade®) and
dexamethasone in patients with relapsed MM.

Carfilzomib is designed to block cancer cells from repairing themselves. If
the cancer cells cannot repair themselves, this may cause them to die.

Velcade is designed to block a protein that causes cells to grow. This may
cause cancer cells to die.

Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other therapy to treat cancer.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase III
Treatment Agents:Bortezomib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Onyx Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults